Across TCGA pan-cancer cohorts, EGR2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated EGR2 data layer compared with 24 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EGR2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EGR2 expression acts as an unfavorable survival marker.
PDAC are the cancer types where EGR2 mass-spec protein most reproducibly stratifies survival.